Format

Send to

Choose Destination
See comment in PubMed Commons below
Clin Cancer Res. 2007 Aug 15;13(16):4825-31.

Erythropoietin and erythropoietin receptor coexpression is associated with poor survival in stage I non-small cell lung cancer.

Author information

1
Service d'Oncologie Médicale, Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris, Université Paris 13, France. pierre.saintigny@avc.aphp.fr

Abstract

PURPOSE:

This study was designed to evaluate the prognostic effect of erythropoietin (EPO) and EPO receptor (EPO-R) expression in stage I non-small cell lung cancer (NSCLC) patients.

EXPERIMENTAL DESIGN:

EPO and EPO-R expression in 158 tumor samples from resected stage I NSCLC was evaluated using immunohistochemistry and tissue array technology.

RESULTS:

EPO-R and EPO were highly expressed in 20.9% and 35.4% of tumors, respectively. High EPO-R expression compared with negative or low-level expression was associated with a poor 5-year disease-specific survival (60.6% versus 80.8%; P = 0.01, log-rank test). High EPO expression compared with negative and low-level expression was associated with a trend toward a poor 5-year disease-specific survival (69.6% versus 80.4%; P = 0.13, log-rank test). A high level of EPO-R and EPO coexpression was associated with a poor 5-year disease-specific survival compared with other groups of patients (50.0% versus 80.0% survival at the end of follow-up; P = 0.005, log-rank test). In multivariate analysis for disease-specific survival, high-level EPO-R and EPO coexpression was an independent prognostic factor for disease-specific survival (hazard ratio, 2.214; 95% confidence interval, 1.012-4.848; P = 0.046).

CONCLUSION:

These results establish the pejorative prognostic value of EPO and EPO-R expression in early-stage resected NSCLC and suggest a potential paracrine and/or autocrine role of endogenous EPO in NSCLC aggressiveness.

Comment in

PMID:
17699861
DOI:
10.1158/1078-0432.CCR-06-3061
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center